Akari Therapeutics Plc Ano de IPO
Qual é o Ano de IPO de Akari Therapeutics Plc?
O Ano de IPO de Akari Therapeutics Plc é 2013
Qual é a definição de Ano de IPO?
A oferta pública inicia (OPI)l é um tipo de oferta pública em que as ações de uma empresa geralmente são vendidas a investidores institucionais que, por sua vez, vendem para o público em geral, em uma bolsa de valores, pela primeira vez.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
Ano de IPO de empresas na Setor Health Care em NASDAQ em comparação com Akari Therapeutics Plc
O que Akari Therapeutics Plc faz?
akari is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. akari’s lead drug, coversin, a second-generation and potentially best-in-class complement inhibitor, acts on complement component-c5, preventing release of c5a and formation of c5b – 9 (also known as the membrane attack complex or mac). coversin is a recombinant small protein (16,740 da) derived from a native protein discovered in the saliva of the ornithodoros moubata tick, where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response.
Empresas com ano de ipo semelhantes a Akari Therapeutics Plc
- AMG Capital Trust II tem Ano de IPO de 2012
- Live Nation Entertainment tem Ano de IPO de 2012
- MGM Resorts International tem Ano de IPO de 2012
- EnerSpar tem Ano de IPO de 2012
- The Western Union tem Ano de IPO de 2012
- Wameja tem Ano de IPO de 2012
- Akari Therapeutics Plc tem Ano de IPO de 2013
- Opus Bank tem Ano de IPO de 2014
- Recro Pharma Inc tem Ano de IPO de 2014
- Radius Recycling tem Ano de IPO de 2014
- Progenity tem Ano de IPO de 2014
- Axalta Coating Systems Ltd tem Ano de IPO de 2014
- Anevia SA tem Ano de IPO de 2014